Lindong Li

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda et al. · Journal of Hepatology · 2021 · 1.5K citations · Full text

Hepatology, Atezolizumab Plus Bevacizumab, Unresectable Hepatocellular Carcinoma +9

IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · Journal of Clinical Oncology · 2021 · 312 citations

Immunodeficiencies, Clinical Endpoint, Pathology +22

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Shukui Qin, Zhenggang Ren, Yin‐Hsun Feng et al. · Liver Cancer · 2021 · 123 citations · Full text

IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.

Arndt Vogel, Philippe Merle, Richard S. Finn et al. · Journal of Clinical Oncology · 2021 · 68 citations

Portal Vein Pressure, Pathology, Multimodality +19

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)

Renchi Yang, Shujie Wang, Xuefeng Wang et al. · Research and Practice in Thrombosis and Haemostasis · 2022 · 65 citations · Full text